Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$45 Mln
P/E Ratio
--
P/B Ratio
0.49
Industry P/E
--
Debt to Equity
0
ROE
-0.16 %
ROCE
-16.12 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-1,598.97 Mln
EBITDA
$-3,009.62 Mln
Net Profit
$-3,114.28 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Connect Biopharma Holdings (CNTB)
| -41.30 | 19.12 | -17.35 | -39.55 | -26.01 | -- | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Connect Biopharma Holdings (CNTB)
| 16.80 | 35.98 | -83.15 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies... using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is headquartered in San Diego, California. Address: 3580 CARMEL MOUNTAIN ROAD, San Diego, CA, United States, 92130 Read more
Co-Founder, President & Chairman of the Board of Directors
Dr. Wubin Pan M.B.A., Ph.D.
Co-Founder, President & Chairman of the Board of Directors
Dr. Wubin Pan M.B.A., Ph.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Connect Biopharma Holdings Limited (CNTB) stood at $ 101 Mln as on 31-Dec-24
The share price of Connect Biopharma Holdings Limited (CNTB) is $0.81 (NASDAQ) as of 29-Apr-2025 16:26 EDT. Connect Biopharma Holdings Limited (CNTB) has given a return of -26.01% in the last 3 years.
Connect Biopharma Holdings Limited (CNTB) has a market capitalisation of $ 45 Mln as on 29-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Connect Biopharma Holdings Limited (CNTB) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Connect Biopharma Holdings Limited (CNTB) and enter the required number of quantities and click on buy to purchase the shares of Connect Biopharma Holdings Limited (CNTB).
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is headquartered in San Diego, California. Address: 3580 CARMEL MOUNTAIN ROAD, San Diego, CA, United States, 92130
The CEO & director of Dr. Wubin Pan M.B.A., Ph.D.. is Connect Biopharma Holdings Limited (CNTB), and CFO & Sr. VP is Dr. Wubin Pan M.B.A., Ph.D..
There is no promoter pledging in Connect Biopharma Holdings Limited (CNTB).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Connect Biopharma Holdings Limited (CNTB) | Ratios |
|---|---|
|
Return on equity(%)
|
-16.18
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-60.03
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Connect Biopharma Holdings Limited (CNTB) was No Profit.
